Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension

BACKGROUND: Ofatumumab has demonstrated superior efficacy and favorable safety for up to 2.5 years versus teriflunomide in relapsing multiple sclerosis (RMS). OBJECTIVE: Further characterize efficacy and safety of ofatumumab in RMS. METHODS: Efficacy set: patients randomized to ofatumumab/teriflunom...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Stephen L, Zielman, Ronald, Das Gupta, Ayan, Xi, Jing, Stoneman, Dee, Karlsson, Goeril, Robertson, Derrick, Cohen, Jeffrey A, Kappos, Ludwig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580679/
https://www.ncbi.nlm.nih.gov/pubmed/37691530
http://dx.doi.org/10.1177/13524585231195346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580679/
https://www.ncbi.nlm.nih.gov/pubmed/37691530
http://dx.doi.org/10.1177/13524585231195346

Ejemplares similares